Algernon Pharmaceuticals Inc.

Algernon is a Canadian clinical stage drug development company investigating multiple drugs with global unmet medical needs. Algernon has active research programs for idiopathic pulmonary fibrosis (“IPF”) with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke. Two of Algernon’s lead drugs are based on drug repurposing and the third compound is a naturally occurring psychedelic drug.

Drug repurposing offers several benefits over traditional drug development including a reduction in investment and risk (repurposed compounds have a much lower risk of failing in human trials as a result of safety issues), shorter research periods and a longer active patent life. Our program specifically investigates compounds that have never been approved in the U.S. or Europe.

We protect our lead compounds with method of use, dosing, and new formulation patents, as well as composition of matter patents that include derivatives and analogues. The Algernon model is highly capital efficient, and the company has assembled an experienced management team, a globally recognized medical and scientific advisory board, and a business advisory board.

Algernon Pharmaceuticals Inc. is a billboard sponsor of Streetwise Reports and paid a fee for this company profile page. Please refer to the important disclosures below for additional details.

Recent Articles:

Biotech Co. Completes Step Toward Psychedelic Treatment for Brain Injuries

Algernon Neuro has completed the third stage of its dosage trial for DMT as a treatment for traumatic brain injury. Read on to see how the company expects to take psychedelics into the mainstream.

Pharmaceutical Company Sets Gold Standard for New Drugs

Algernon Pharmaceuticals Inc. has received a U.S. patent for a ground-breaking new Non-Alcoholic Steatohepatitis (NASH) drug under investigation, and is developing another for refractory chronic cough (RCC). Click here to read how the company is repurposing these two treatments with drugs that have a known safety history.

Biotech Co. Set To Reach New Highs

Algernon Pharmaceuticals Inc. and its subsidiary Algernon NeuroScience have reached a new milestone in a clinical trial investigating the psychedelic drug DMT for the treatment of brain injuries. Click here to learn more about new applications for psychedelics.

Former NFL Safety Director Joins Neurotherapy Firm Advisory Board

Treating traumatic brain injury with alternative pharmaceuticals is delicate work. Now one Canadian firm has enlisted the help of former National Football League Neurological Player Care Safety Director Dr. David Brody.

Tech. Analyst Says Pharma Co. Is at a Favorable Risk/Reward Ratio

Contributed Opinion
Technical analyst Clive Maund reviews Algernon Pharmaceuticals Inc.'s 6-month, 3-year, and 9-year charts to tell you whether you should be interested in this pharma company.

Why One Fund Owns 13% of This Small-Cap Pharma

Clinical-stage Algernon Pharmaceuticals' multiple pipelines include testing a psychedelic for the treatment of stroke, and testing other drugs for idiopathic pulmonary fibrosis and chronic kidney disease.

More Articles

Expert Comments:

Clive Maund,

"The case for buying Algernon Pharmaceuticals Inc. here is clear and compelling. . .the company has developed a highly effective product and its stock is silly cheap and so a good investment. There is a good chance for obvious reasons that some larger company will show up and buy Algernon out."

headshot of Douglas Loe

Douglas Loe, Leede Jones Gable

"Algernon Pharmaceuticals Inc. intends to initiate a 180-patient Phase 2b trial assessing the company's lead N-methyl-D-aspartate receptor antagonist ifenprodil/NP-120 as a treatment for chronic cough. The firm intends to commence the trial by Q3/23."

Clive Maund,

"Algernon Pharmaceuticals Inc. has two things going for it. One is that it could come out with positive news at any time that could get the stock moving, and the other is that with only 2.3M shares in issue, when it does move, it is likely to result in big percentage gains. . .the company is therefore rated a Strong Speculative Buy."

headshot of Dr. André Uddin

Dr. André Uddin, Research Capital Corporation

"Positive Phase 2a data was previously achieved with Algernon Pharmaceuticals Inc.'s ifenprodil in idiopathic pulmonary fibrosis and chronic cough. . .we believe management is going to hone most of its efforts on its lead candidate ifenprodil for chronic cough and advance it into Phase 2b trials."

Clive Maund,

"Algernon Pharmaceuticals Inc. got sold down further than we expected, making an unexpected further drop last week that took it down close to a trend line connecting a series of lows; however the company now looks set to reverse to the upside, especially as this morning it came out with the news that it has entered into a clinical trial agreement with Yale University for a DMT Phase 2 depression study. . .anyone holding should therefore stay long, and Algernon is rated a Buy again here."

Clive Maund,

"Algernon Pharmaceuticals Inc. has reacted back further than expected with the result that it has arrived back in a zone of strong support where a string of bullish candles has formed since early this month. It is deeply oversold here on its moving average convergence-divergence (MACD) and relative to its moving averages, with the normalizing MACD histogram (bars) calling for a rally soon, especially as we have only seen upside volume in recent days. . .the company is rated an immediate Strong Buy."

More Expert Comments

Experts Following This Company

Clive Maund –
headshot of Dr. André Uddin
Dr. André Uddin – Research Capital Corporation

Company News 

9/6/2023 – Algernon Pharmaceuticals Announces Grant of U.S. Patent for Repirinast in NAFLD and NASH

8/8/2023 – Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

7/14/2023 – Algernon Pharmaceuticals Announces Private Placement and Issuance of Shares in Connection with Financial Advisory Agreement

5/31/2023 – Algernon Pharmaceuticals Receives Notice of Allowance from the Japanese Patent Office for Repirinast and the Treatment of CKD

Important Disclosures
Algernon Pharmaceuticals Inc. is a Billboard advertiser of Streetwise Reports and pays a flat fee. Fees fund both sponsor-specific activities and general report activities. Sponsor-specific activities may include aggregating content and publishing that content on the Streetwise Reports site, creating and maintaining company landing pages, interviewing key management, posting a banner/billboard, and/or issuing press releases. The fees also cover the costs for Streetwise Reports to publish and syndicate investment opinion and comments, and also to curate or create sector-specific content. Billboard advertising monthly fees range from $3,000 to $5,000. This landing page contains a summary of the company that was prepared by that company. Some landing pages contain investing highlights and a catalyst calendar that are prepared by that company. The Expert Comments and Experts Following This Company sections of the landing page are compiled by Streetwise Reports. There may be other information about the company that is not placed on the landing page, and Streetwise Reports does not guarantee the accuracy or thoroughness of the information contained on the landing page. Readers should conduct their own research for all information publicly available concerning the company. This landing page may be considered advertising for the purposes of 18 U.S.C. 1734.

streetwise book logo Streetwise Company Fact Sheet

Streetwise - Algernon Pharmaceuticals Inc. Ownership Overview*

Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGN0:XFRA)

*Share Structure as of 4/13/2023
Investing Highlights
Advancing new drug treatments for billion dollar global disease markets.
Conducting multiple phase II clinical trials
Experienced management team & globally recognized medical advisory board
catalyst Calendar
Begin Phase 1 Study | DMT/TROKE
US FDA IND filing / Fast Track Application | IPF / COUGH
Begin Phase 2b Study | IPF / COUGH
Phase 1 DMT Data | DMT/ STROKE
Begin Phase 1 Study | CKD
Phase 2b Study | CHRONIC COUGH
Begin Phase 2 | DMT / STROKE